Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CAR T-cell therapy effective for r/r B-cell lymphoma of the GI tract

Key clinical point: CAR T-cell therapy was effective for gastrointestinal relapsed/refractory B-cell lymphoma.

Major finding: An objective response was achieved in 10/14 patients, with 7 achieving a complete response.

Study details: Open-label, single-center study of infusion of anti-CD22 and anti-CD19 CAR T cells in 14 patients with r/r B-cell malignancies involving the GI tract.

Disclosures: The study was funded by the National Science Foundation of China. The authors reported they had no conflicts of interest.

Citation:

Zheng C et al. Cytotherapy. 2020;22:166-71.